Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy

Bone

Volumn 26, Issue 5, 2000, Pages 505-511

  Christgau, S ^a   Bitsch Jensen, O ^a   Hanover Bjarnason, N ^b   Gamwell Henriksen, E ^a   Qvist, P ^a   Alexandersen, P ^b   Bang Henriksen, D ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Antiresorptive therapy; Biochemical markers; Biological variation; Bone resorption

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCIUM; COLLAGEN TYPE 1; EPITOPE; ESTRADIOL; NORETHISTERONE; OSTEOCALCIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE MINERAL; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONITORING; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN CROSS LINKING; SAMPLING; SPINE; TECHNIQUE;

ALENDRONATE; BONE DENSITY; BONE RESORPTION; CIRCADIAN RHYTHM; CLINICAL TRIALS; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 0034083361     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00248-9     Document Type: Article

References (29)

1. Aerssens J., Declerc K., Maeyert B., Boonen S., Dequeker J. The effect of modifying dietary calcium intake pattern on the circadian rhythm of bone resorption. Calcif Tissue Int. 65:1999;34-40.
2. Bauer D.C., Sklarin P.M., Stone K.L., Black D.M., Nevitt M.C., Ensrud K.E., Arnaud C.A., Genant H.K., Garnero P., Delmas D., Lawaetz H., Cummings S.R. Biochemical markers of bone turnover and prediction of hip bone loss in older women The study of osteoporotic fractures . J Bone Miner Res. 14:1999;1404-1410.
3. Bjarnason, N. H. and Christiansen, C. An early response in biochemical markers predicts long term response in bone mass during HRT in early postmenopausal women. Bone. In press.
4. Bjarnason N.H., Hassager C., Christiansen C. Postmenopausal bone remodeling and hormone replacement. Climacteric. 1:1998;72-79.
5. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CTx) Follow-up on hormone replacement therapy and osteoporosis risk assessment . J Clin Endocrinol Metab. 80:1995;864-868.
6. Christgau S., Bjarnason N.H., Rigault M.Y., Pedersen B.J., Littau M., Heelsberg M., Rosenquist C. Intra-individual variation and response to anti-resorptive therapy assessed by bone resorption measurements with the serum CTx™ One Step ELISA. Ligand Assay. 3:1998;200-205.
7. Christgau S., Rosenquist C., Alexandersen P., Bjarnason N.H., Ravn P., Fledelius C., Herling C., Qvist P., Christiansen C. Clinical evaluation of the Serum CTx™ One Step ELISA, a new assay measuring the serum concentration of bone derived degradation products of type I collagen C-telopeptides. Clin Chem. 44:1998;2290-2301.
8. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Hustler W.J., Draper M., Christainsen C. The effects of raloxifene on bone mineral density, serum cholesterol and uterine endometrium in post-menopausal women. N Engl J. 337:1997;1641-1648.
9. Eyre D.R. Bone biomarkers as tools in osteoporosis management. Spine. 22:(Suppl.):1997;17S-24S.
10. 1 chain of type I collagen. J Biol Chem. 272:1997;9755-9763.
11. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopause. J Clin Endocrinol Metab. 79:1994;1693-1700.
12. Genant H.K., Jergas M., Palermo L., Nevitt M., Valentin R.S., Black D., Cummings S.R. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures research group. J Bone Miner Res. 11:1996;984-996.
13. Gerrits M.I., Vecht-Hart I.M., Oldenhave A., Thijssen J.H.H. Comparison of urinary bone resorption markers in women of 40-70 years; day-to-day and long term variation in individual subjects. Maturitas. 30:1998;247-255.
14. Hannon R.A., Bluhmson A., Naylor K.E., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy. Implication of biological variability. J Bone Miner Res. 13:1998;1124-1133.
15. McClung C., Clemmensen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., Fuleihan G., Reda C., Yates A.J., Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, placebo controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 128:1998;253-261.
16. Kanis J.A. Biochemical markers in osteoporosis. Scand J Clin Lab Invest. 57:(Suppl. 227):1997;6-11.
17. Machado A.B.C., Hannon R.A., Eastell R. Monitoring Alendronate therapy for osteoporosis. J Bone Miner Res. 14:1999;602-608.
18. Nguyen T.V., Sambrook P.N., Eisman J.A. Source of variability in bone mineral density measurements Implications for study design and analysis of bone loss . J Bone Miner Res. 12:1997;124-135.
19. Pedersen B.J., Ravn P., Bonde M. Type I collagen C-telopeptide degradation products as bone resorption markers. J Clin Ligand Assay. 21:1998;118-127.
20. Popp-Snijders C., Lips P., Netelenbos J.C. Intra-individual variation in bone resorption markers in urine. Ann Clin Biochem. 33:1996;347-348.
21. Ravaud P., Reny J.L., Giraudeau B., Porcher R., Dougados M., Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res. 14:1999;1449-1456.
22. Ravn P., Clemmensen B., Christiansen C. Biochemical markers can predict the response in bone mass during Alendronate treatment in elderly postmenopausal women. Bone. 24:1999;237-244.
23. Ravn P., Clemmensen B., Juel Riis B., Overgaard K., Christiansen C. The effect of bone mass and bone markers of different doses of Ibandronate A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double blind, placebo-controlled, dose-finding study . Bone. 19:1996;527-533.
24. Rodan G.A., Fleish H. Bisphosphonates Mechanism of action . J Clin Invest. 97:1996;2692-2696.
25. Rosen, H. N., Moses, A. C., Gaber, J., Iloputaife, I. D., Ross, D. S., Lee, S. L., and Greenspan, S. L. Serum CTx: A new marker of bone resorption which shows treatment effect more often than other markers because of low CV and large changes with bisphosphonate therapy. Calcif Tissue Int. In press.
26. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Christiansen C. The serum CTx™ One Step ELISA, The first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 44:1998;2281-2289.
27. Rosenquist C., Qvist P., Bjarnason N., Christiansen C. Measurement of a more stable structure of osteocalcin in human serum using two monoclonal antibodies in an enzyme linked immunosorbent assay (ELISA). Clin Chem. 41:1995;1439-1445.
28. Schlemmer A., Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol. 140:1999;332-337.
29. Watts N.B. Clinical utility of biochemical markers of bone resorption. Clin Chem. 45:1999;1359-1368.